Ventyx Biosciences downgraded by Stifel with a new price target
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded Ventyx Biosciences from Buy to Hold and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | $12.00 | Perform → Outperform | Oppenheimer |
| 3/12/2024 | $7.00 → $16.00 | Equal Weight → Overweight | Wells Fargo |
| 11/7/2023 | $46.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/7/2023 | Outperform → Perform | Oppenheimer | |
| 11/7/2023 | Buy → Neutral | H.C. Wainwright | |
| 11/7/2023 | $6.00 | Buy → Hold | Stifel |
| 11/7/2023 | $77.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 6/14/2023 | $63.00 | Outperform | Credit Suisse |
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a partner or other nondilutive financing for pivotal Phase 3 trial Based on pipeline reprioritization and recent PIPE financing, Ventyx expects its current cash, cash equivalents and marketable securit
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: Wednesday, February 12, 2025Time: 2:40-3:10 PM ET A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will a
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson's disease expected in H1 2025 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 (unaudited) expected to fund operations into at least H2 2026 SAN DIEGO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-st
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: •Event: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 4:10-4:40 PM ET •Event: Jefferies London Healthcare Conference Location: London, UK Date: Wednesday, November 20, 2024 Time: 8:00-8:25 AM GMT •Event: Piper Sandler Healthcare Conference Location: New York,
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to
ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors. Dr. Hulme and Ms. Cadoret-Manier are both successful executives who each bring a wealth of knowledge from more than 30 years of experience in biotech and pharmaceutical drug development and commercialization. Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeo
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00
Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously
Morgan Stanley downgraded Ventyx Biosciences from Overweight to Equal-Weight and set a new price target of $6.00 from $46.00 previously
SCHEDULE 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)
SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SCHEDULE 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)